Home - Novel DX

Gov. Wes Moore and Maryland Department of Commerce Award $633K Grant to Novel Microdevices

Novel Microdevices, Inc. has been awarded $633,757 through the Build Our Future Grant Pilot Program by the Maryland Department of Commerce. The grant will support the establishment of a GMP-compliant pilot manufacturing facility at the company’s Baltimore City headquarters for production of innovative microfluidic cartridges used in its sample-to-answer diagnostic platform. This facility will enable scaling to fully automated custom manufacturing lines, accelerating delivery of 15-minute PCR tests for infectious diseases like Flu, RSV, COVID-19, and STIs at the point of care.

LEARN MORE

Novel Microdevices 2024 Mayor's Awards Profile

Novel Microdevices, Inc. is a leader in medical diagnostic innovation, recently announcing the award of an additional $2.68 million in follow-on funding from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech program.

Watch

Novel Microdevices Secures $2.7 Million in Follow-On Funding from NIH RADx® Tech Program After Achieving Key Milestones

Novel Microdevices, Inc., a leader in medical diagnostic innovation, announces the award of an additional $2.68 million in follow-on funding from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech program. The funding follows the successful completion of critical performance milestones for its high-performance, point-of-care RT-PCR platform, which rapidly detects RSV, Influenza A, Influenza B, and COVID-19 in just 15 minutes.

Learn More

Revolutionary Technology

Novel Microdevices’ rapid point-of-care diagnostic is designed for portability, weighing only four pounds. It is battery-powered, making it particularly suited to low resource settings and low-and middle-income countries (LMICs).

The molecular testing platform implements polymerase chain reaction (PCR) technology on a disposable cartridge. The patient sample is added to the cartridge, which is then inserted into the Novel Dx system, which analyzes the genetic sequence of cells to identify disease and the presence of genetic mutations known to make bacteria resistant to antibiotics.

Contact Us

Gov. Wes Moore and Maryland Department of Commerce Award $633K Grant to Novel Microdevices

Novel Microdevices, Inc. has been awarded $633,757 through the Build Our Future Grant Pilot Program by the Maryland Department of Commerce. The grant will support the establishment of a GMP-compliant pilot manufacturing facility at the company’s Baltimore City headquarters for production of innovative microfluidic cartridges used in its sample-to-answer diagnostic platform. This facility will enable scaling to fully automated custom manufacturing lines, accelerating delivery of 15-minute PCR tests for infectious diseases like Flu, RSV, COVID-19, and STIs at the point of care.

LEARN MORE

Novel Microdevices 2024 Mayor's Awards Profile

Novel Microdevices, Inc. is a leader in medical diagnostic innovation, recently announcing the award of an additional $2.68 million in follow-on funding from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech program.

Watch

Novel Microdevices Secures $2.7 Million in Follow-On Funding from NIH RADx® Tech Program After Achieving Key Milestones

Novel Microdevices, Inc., a leader in medical diagnostic innovation, announces the award of an additional $2.68 million in follow-on funding from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech program. The funding follows the successful completion of critical performance milestones for its high-performance, point-of-care RT-PCR platform, which rapidly detects RSV, Influenza A, Influenza B, and COVID-19 in just 15 minutes.

Learn More

How it Works

Lab Quality and Clinically-Actionable Results in Minutes

The Novel Dx device detects the genetic material of pathogens using Nucleic Acid Amplification Techniques (NAAT). These are the same methods utilized by clinical reference laboratories. Novel Dx delivers lab-quality results in under 15 minutes so patients are tested, diagnosed, and treated in the same visit.